Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company advancing novel bispecific antibody therapies for cancer treatment. This news hub provides investors and industry professionals with timely updates on APVO's clinical developments, platform innovations, and strategic milestones.
Our curated collection features official press releases and verified news about the company's ADAPTIR platform progress, clinical trial results for candidates like mipletamig in AML, and regulatory updates. Users will find updates on financial filings, research collaborations, and therapeutic pipeline expansions across hematologic malignancies and solid tumors.
This resource serves as a centralized reference for tracking APVO's progress in developing targeted immunotherapies designed to improve treatment safety and efficacy. Content is organized chronologically with clear sourcing to ensure reliable tracking of the company's scientific advancements and corporate developments.
Bookmark this page for streamlined access to APVO's latest announcements, including trial initiations, data presentations at medical conferences, and partnership disclosures. Check regularly for updates on how the company's modular protein engineering approaches aim to address unmet needs in oncology care.
Aptevo Therapeutics (NASDAQ: APVO) announced its participation in The Protein & Antibody Engineering Summit (PEGS) in Boston, MA, where they will present their strategies for designing bispecific drug candidates. Dr. Peter Pavlik, Senior Director of Protein Engineering, will lead the session, focusing on early functional screening and multiple screening formats to predict outcomes. The company has developed a portfolio of candidates, including clinical-stage APVO436 and ALG.APV-527 and preclinical APVO603, APVO711, and APVO442. Recent clinical updates include a breast cancer patient in the ALG.APV-527 trial showing stable disease for over eleven months and plans to start a dose optimization trial for APVO436 in AML patients in Q2 2024.
Aptevo Therapeutics Inc. reported positive outcomes from its clinical trials, with a breast cancer patient showing stable disease for over eleven months on a higher dose level. The company is set to start a dose optimization trial for APVO436 in 2Q 2024. Financially, Aptevo's cash position was $10.3 million as of March 31, 2024, with reduced research and development expenses and general administrative expenses. However, the company reported a net loss of $6.8 million for the quarter.
FAQ
What is the current stock price of Aptevo Therapeutics (APVO)?
What is the market cap of Aptevo Therapeutics (APVO)?
